Ironwood Pharmaceuticals, Inc.  

(Public, NASDAQ:IRWD)   Watch this stock  
Find more results for IRWD
-0.09 (-0.73%)
Real-time:   10:16AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 12.17 - 12.50
52 week 9.77 - 17.11
Open 12.32
Vol / Avg. 106,307.00/1.18M
Mkt cap 1.74B
P/E     -
Div/yield     -
EPS -1.17
Shares 126.82M
Beta 1.36
Inst. own 115%
Feb 10, 2016
Q4 2015 Ironwood Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 11, 2015
Ironwood Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Nov 3, 2015
Q3 2015 Ironwood Pharmaceuticals Inc Earnings Call - Webcast
Nov 3, 2015
Q3 2015 Ironwood Pharmaceuticals Inc Earnings Release
Nov 3, 2015
Ironwood Pharmaceuticals Inc at �EBD BIO Europe- Fall
Sep 17, 2015
Ironwood Pharmaceuticals Inc at Morgan Stanley Healthcare Conference
Sep 16, 2015
Ironwood Pharmaceuticals Inc at EBD Group BioPharm America
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -119.76% -248.07%
Operating margin -66.17% -221.58%
EBITD margin - -205.45%
Return on average assets -30.00% -62.35%
Return on average equity -157.91% -299.14%
Employees 464 -
CDP Score - -


301 Binney St
CAMBRIDGE, MA 02142-1030
United States - Map
+1-617-6217722 (Phone)
+1-617-4940480 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company has a product, linaclotide, which is available in the United States and Mexico under the brand name LINZESS, and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.

Officers and directors

Bryan E. Roberts Ph.D. Independent Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
Peter M. Hecht Ph.D. Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Thomas Graney Chief Financial Officer, Senior Vice President - Finance, Corporate Strategy
Age: 50
Bio & Compensation  - Reuters
Mark G. Currie Ph.D. Senior Vice President, Chief Scientific Officer, President - Research and Development
Age: 60
Bio & Compensation  - Reuters
Thomas A. McCourt Senior Vice President - Marketing and Sales, Chief Commercial Officer
Age: 57
Bio & Compensation  - Reuters
Halley E. Gilbert Esq. Senior Vice President, Chief Legal Officer, Secretary
Age: 45
Bio & Compensation  - Reuters
George H. Conrades Independent Director
Age: 76
Bio & Compensation  - Reuters
Marsha H. Fanucci Independent Director
Age: 61
Bio & Compensation  - Reuters
Terrance G. McGuire Independent Director
Age: 59
Bio & Compensation  - Reuters
Julie H. McHugh Independent Director
Age: 50
Bio & Compensation  - Reuters